[{"id":"e3849c3a-6be4-415c-bb15-50c8c05581ff","acronym":"","url":"https://clinicaltrials.gov/study/NCT07190833","created_at":"2025-09-27T08:40:11.891Z","updated_at":"2025-09-27T08:40:11.891Z","phase":"Phase 1","brief_title":"A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)","source_id_and_acronym":"NCT07190833","lead_sponsor":"Bionoxx Inc.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • hydroxyurea"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 11/01/2025","start_date":" 11/01/2025","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 12/01/2030","study_completion_date":" 12/01/2030","last_update_posted":"2025-09-24"},{"id":"d70dbe69-fc0c-4491-b69e-8481a8fc0c63","acronym":"","url":"https://clinicaltrials.gov/study/NCT07170592","created_at":"2025-09-20T07:09:01.411Z","updated_at":"2025-09-20T07:09:01.411Z","phase":"Phase 1","brief_title":"A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients","source_id_and_acronym":"NCT07170592","lead_sponsor":"Bionoxx Inc.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • hydroxyurea"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 12/01/2025","start_date":" 12/01/2025","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 12/01/2030","study_completion_date":" 12/01/2030","last_update_posted":"2025-09-12"},{"id":"20ec0814-6de7-4db9-a034-30ef491a8c51","acronym":"","url":"https://clinicaltrials.gov/study/NCT05526924","created_at":"2022-09-02T17:00:19.091Z","updated_at":"2025-02-25T16:27:01.989Z","phase":"Phase 1","brief_title":"Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer","source_id_and_acronym":"NCT05526924","lead_sponsor":"University of Chicago","biomarkers":" PD-L1 • PD-1","pipe":"","alterations":" ","tags":["PD-L1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • Partruvix (pamiparib) • hydroxyurea • fluorouracil topical"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/07/2023","start_date":" 03/07/2023","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-11-22"},{"id":"9dd1dfec-0aa4-4556-89c3-d62638f6b981","acronym":"","url":"https://clinicaltrials.gov/study/NCT03761914","created_at":"2021-01-18T18:29:09.264Z","updated_at":"2025-02-25T16:08:40.101Z","phase":"Phase 1/2","brief_title":"Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers","source_id_and_acronym":"NCT03761914","lead_sponsor":"Sellas Life Sciences Group","biomarkers":" HER-2 • KRAS • PGR • WT1 • BRCA • MUC16","pipe":" | ","alterations":" HER-2 negative • KRAS wild-type • RAS wild-type • BRCA mutation","tags":["HER-2 • KRAS • PGR • WT1 • BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • KRAS wild-type • RAS wild-type • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • oxaliplatin • irinotecan • Zeltherva (galinpepimut-S) • hydroxyurea • Leukine (sargramostim)"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 09/30/2019","start_date":" 09/30/2019","primary_txt":" Primary completion: 07/05/2022","primary_completion_date":" 07/05/2022","study_txt":" Completion: 10/27/2022","study_completion_date":" 10/27/2022","last_update_posted":"2024-11-19"},{"id":"a93ec7ac-af54-43ee-8608-d8c37dfbf77a","acronym":"DEPEND","url":"https://clinicaltrials.gov/study/NCT03944915","created_at":"2025-02-26T07:16:24.948Z","updated_at":"2025-02-26T07:16:24.948Z","phase":"Phase 2","brief_title":"De-Escalation Therapy for Human Papillomavirus Negative Disease","source_id_and_acronym":"NCT03944915 - DEPEND","lead_sponsor":"University of Chicago","biomarkers":" TMB","pipe":"","alterations":" ","tags":["TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • carboplatin • paclitaxel • 5-fluorouracil • hydroxyurea • Neupogen (filgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 08/26/2019","start_date":" 08/26/2019","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-08-15"},{"id":"9b677f8f-b3e7-4b6d-8718-36c028b32cda","acronym":"","url":"https://clinicaltrials.gov/study/NCT04329325","created_at":"2022-04-24T09:02:32.988Z","updated_at":"2024-07-02T16:35:00.993Z","phase":"Phase 2","brief_title":"Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT04329325","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" BCR-ABL1 fusion","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • Blincyto (blinatumomab) • dexamethasone • hydroxyurea"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 17","initiation":"Initiation: 03/30/2020","start_date":" 03/30/2020","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-05-24"},{"id":"66937713-e1c8-4e82-bb66-47047e56b479","acronym":"IDHENTIFY","url":"https://clinicaltrials.gov/study/NCT02577406","created_at":"2021-03-25T18:30:43.571Z","updated_at":"2024-07-02T16:35:06.839Z","phase":"Phase 3","brief_title":"An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation","source_id_and_acronym":"NCT02577406 - IDHENTIFY","lead_sponsor":"Celgene","biomarkers":" IDH2 • UGT1A1","pipe":" | ","alterations":" IDH2 mutation • UGT1A1*1*1 • UGT1A1 mutation","tags":["IDH2 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • UGT1A1*1*1 • UGT1A1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • azacitidine • Idhifa (enasidenib) • hydroxyurea"],"overall_status":"Completed","enrollment":" Enrollment 319","initiation":"Initiation: 12/30/2015","start_date":" 12/30/2015","primary_txt":" Primary completion: 03/17/2020","primary_completion_date":" 03/17/2020","study_txt":" Completion: 03/25/2024","study_completion_date":" 03/25/2024","last_update_posted":"2024-04-30"},{"id":"e36ce158-5d2c-43a5-8d9f-4bf96a854310","acronym":"ALLO-BAT","url":"https://clinicaltrials.gov/study/NCT04217356","created_at":"2021-01-18T20:31:57.752Z","updated_at":"2024-07-02T16:35:13.310Z","phase":"","brief_title":"Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis","source_id_and_acronym":"NCT04217356 - ALLO-BAT","lead_sponsor":"University Health Network, Toronto","biomarkers":" TP53 • IDH1 • IDH2 • JAK2 • ASXL1 • SRSF2 • U2AF1 • CALR","pipe":" | ","alterations":" TP53 mutation • ASXL1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation • CALR mutation","tags":["TP53 • IDH1 • IDH2 • JAK2 • ASXL1 • SRSF2 • U2AF1 • CALR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • ASXL1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation • CALR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib) • hydroxyurea"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 08/05/2020","start_date":" 08/05/2020","primary_txt":" Primary completion: 08/05/2025","primary_completion_date":" 08/05/2025","study_txt":" Completion: 02/05/2026","study_completion_date":" 02/05/2026","last_update_posted":"2024-03-22"},{"id":"894cf8cb-0456-4299-b86d-2ea4d23be60a","acronym":"BMP-MDS","url":"https://clinicaltrials.gov/study/NCT06175923","created_at":"2023-12-20T06:19:40.931Z","updated_at":"2024-07-02T16:35:22.504Z","phase":"","brief_title":"Role of BMP Pathway in MDS Progression","source_id_and_acronym":"NCT06175923 - BMP-MDS","lead_sponsor":"Hospices Civils de Lyon","biomarkers":" BMP2 • BMP4","pipe":"","alterations":" ","tags":["BMP2 • BMP4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • hydroxyurea"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/27/2024","start_date":" 01/27/2024","primary_txt":" Primary completion: 01/27/2029","primary_completion_date":" 01/27/2029","study_txt":" Completion: 01/27/2034","study_completion_date":" 01/27/2034","last_update_posted":"2024-01-23"},{"id":"c2957436-cc4b-46f1-b57e-c905761bf625","acronym":"","url":"https://clinicaltrials.gov/study/NCT02626715","created_at":"2021-01-18T12:45:57.284Z","updated_at":"2024-07-02T16:35:25.740Z","phase":"Phase 2","brief_title":"Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS","source_id_and_acronym":"NCT02626715","lead_sponsor":"Randy Windreich","biomarkers":" FLT3 • CD34","pipe":" | ","alterations":" FLT3 positive","tags":["FLT3 • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Campath (alemtuzumab) • melphalan • fludarabine IV • hydroxyurea • thiotepa • busulfan"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 09/04/2015","start_date":" 09/04/2015","primary_txt":" Primary completion: 04/12/2023","primary_completion_date":" 04/12/2023","study_txt":" Completion: 04/12/2023","study_completion_date":" 04/12/2023","last_update_posted":"2023-12-19"},{"id":"c1091e4c-1522-4ef8-a73b-fc49b73dd693","acronym":"","url":"https://clinicaltrials.gov/study/NCT01657682","created_at":"2021-01-18T07:09:01.814Z","updated_at":"2024-07-02T16:35:27.592Z","phase":"Phase 2","brief_title":"A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations","source_id_and_acronym":"NCT01657682","lead_sponsor":"Arog Pharmaceuticals, Inc.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e crenolanib (ARO-002) • hydroxyurea"],"overall_status":"Completed","enrollment":" Enrollment 56","initiation":"Initiation: 10/01/2012","start_date":" 10/01/2012","primary_txt":" Primary completion: 04/01/2019","primary_completion_date":" 04/01/2019","study_txt":" Completion: 04/01/2019","study_completion_date":" 04/01/2019","last_update_posted":"2023-11-30"},{"id":"4c2fc1fb-e66a-4255-b1b5-1f24873e7431","acronym":"","url":"https://clinicaltrials.gov/study/NCT03974217","created_at":"2021-01-18T19:32:53.912Z","updated_at":"2024-07-02T16:35:44.626Z","phase":"Phase 1","brief_title":"Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts","source_id_and_acronym":"NCT03974217","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" TMB • FLT3 • IDH1 • IDH2 • STAG2 • RAD21 • SMC1A • SMC3","pipe":" | ","alterations":" STAG2 mutation","tags":["TMB • FLT3 • IDH1 • IDH2 • STAG2 • RAD21 • SMC1A • SMC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e STAG2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Talzenna (talazoparib) • decitabine • hydroxyurea"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 08/01/2019","start_date":" 08/01/2019","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-06-27"},{"id":"efb2f664-87fd-4928-b92b-66faede8e3da","acronym":"HQP1351CC203","url":"https://clinicaltrials.gov/study/NCT04126681","created_at":"2021-01-18T20:09:35.310Z","updated_at":"2024-07-02T16:35:51.472Z","phase":"Phase 2","brief_title":"A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase","source_id_and_acronym":"NCT04126681 - HQP1351CC203","lead_sponsor":"Ascentage Pharma Group Inc.","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib • nilotinib • Nailike (olverembatinib) • Synribo (omacetaxine mepesuccinate) • hydroxyurea"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 144","initiation":"Initiation: 10/21/2019","start_date":" 10/21/2019","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-04-04"},{"id":"295272f8-aec7-4d92-83ea-e03a6cde0d00","acronym":"GFM-DAC-CMML","url":"https://clinicaltrials.gov/study/NCT02214407","created_at":"2022-04-24T08:56:51.932Z","updated_at":"2024-07-02T16:36:20.482Z","phase":"Phase 3","brief_title":"Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML","source_id_and_acronym":"NCT02214407 - GFM-DAC-CMML","lead_sponsor":"Groupe Francophone des Myelodysplasies","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e decitabine • hydroxyurea"],"overall_status":"Completed","enrollment":" Enrollment 170","initiation":"Initiation: 10/14/2014","start_date":" 10/14/2014","primary_txt":" Primary completion: 07/05/2021","primary_completion_date":" 07/05/2021","study_txt":" Completion: 08/16/2021","study_completion_date":" 08/16/2021","last_update_posted":"2021-11-19"},{"id":"70a14a13-f51d-4a8e-b7a5-ae3fdaedca67","acronym":"","url":"https://clinicaltrials.gov/study/NCT02788201","created_at":"2021-01-29T07:12:16.767Z","updated_at":"2024-07-02T16:36:38.979Z","phase":"Phase 2","brief_title":"Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma","source_id_and_acronym":"NCT02788201","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Xalkori (crizotinib) • erlotinib • carboplatin • sorafenib • paclitaxel • docetaxel • sunitinib • tamoxifen • cytarabine • bortezomib • doxorubicin hydrochloride • azacitidine • Jakafi (ruxolitinib) • oxaliplatin • irinotecan • Halaven (eribulin mesylate) • epirubicin • carmustine • Vumon (teniposide) • hydroxyurea • Zanosar (streptozocin)"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 03/27/2017","start_date":" 03/27/2017","primary_txt":" Primary completion: 10/23/2019","primary_completion_date":" 10/23/2019","study_txt":" Completion: 10/23/2019","study_completion_date":" 10/23/2019","last_update_posted":"2020-11-06"},{"id":"8581491d-374e-47d8-8cf7-20ff1d417401","acronym":"","url":"https://clinicaltrials.gov/study/NCT02017457","created_at":"2021-01-18T09:13:52.590Z","updated_at":"2025-02-25T14:34:27.169Z","phase":"Phase 2","brief_title":"Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation.","source_id_and_acronym":"NCT02017457","lead_sponsor":"Carlos Graux, MD, PhD","biomarkers":" NPM1 • WT1 • HLA-DRB1 • CEBPA • HLA-DQB1 • HLA-B • HLA-C","pipe":" | ","alterations":" MLL-PTD","tags":["NPM1 • WT1 • HLA-DRB1 • CEBPA • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL-PTD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • hydroxyurea"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 12/01/2013","start_date":" 12/01/2013","primary_txt":" Primary completion: 11/01/2019","primary_completion_date":" 11/01/2019","study_txt":" Completion: 11/01/2019","study_completion_date":" 11/01/2019","last_update_posted":"2019-12-10"},{"id":"c2127c94-b5aa-4264-be7a-ee93fa6a03a5","acronym":"","url":"https://clinicaltrials.gov/study/NCT01259856","created_at":"2021-01-18T05:04:56.061Z","updated_at":"2024-07-02T16:37:00.069Z","phase":"Phase 3","brief_title":"Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)","source_id_and_acronym":"NCT01259856","lead_sponsor":"Ronald Hoffman","biomarkers":" JAK2","pipe":" | ","alterations":" JAK2 V617F","tags":["JAK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 V617F"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pegasys (pegylated interferon α -2a) • hydroxyurea • aspirin"],"overall_status":"Completed","enrollment":" Enrollment 168","initiation":"Initiation: 09/01/2011","start_date":" 09/01/2011","primary_txt":" Primary completion: 06/30/2017","primary_completion_date":" 06/30/2017","study_txt":" Completion: 06/30/2017","study_completion_date":" 06/30/2017","last_update_posted":"2019-04-30"},{"id":"002f2361-8b0d-4b57-a06b-10766598b736","acronym":"","url":"https://clinicaltrials.gov/study/NCT00055874","created_at":"2022-04-24T08:54:00.358Z","updated_at":"2024-07-02T16:37:11.014Z","phase":"Phase 3","brief_title":"Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia","source_id_and_acronym":"NCT00055874","lead_sponsor":"Heidelberg University","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • cytarabine • hydroxyurea"],"overall_status":"Completed","enrollment":" Enrollment 1551","initiation":"Initiation: 06/01/2002","start_date":" 06/01/2002","primary_txt":" Primary completion: 03/31/2012","primary_completion_date":" 03/31/2012","study_txt":" Completion: 03/31/2017","study_completion_date":" 03/31/2017","last_update_posted":"2018-05-03"},{"id":"bb338bc0-84a5-416d-9940-f963dcb3cec6","acronym":"FAST","url":"https://clinicaltrials.gov/study/NCT02611973","created_at":"2021-01-18T12:41:23.906Z","updated_at":"2024-07-02T16:37:19.528Z","phase":"Phase 3","brief_title":"Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia","source_id_and_acronym":"NCT02611973 - FAST","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" JAK2 • CALR","pipe":" | ","alterations":" JAK2 V617F • CALR mutation","tags":["JAK2 • CALR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 V617F • CALR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e hydroxyurea • aspirin"],"overall_status":"Recruiting","enrollment":" Enrollment 2250","initiation":"Initiation: 03/10/2016","start_date":" 03/10/2016","primary_txt":" Primary completion: 11/01/2019","primary_completion_date":" 11/01/2019","study_txt":" Completion: 11/01/2022","study_completion_date":" 11/01/2022","last_update_posted":"2017-07-26"},{"id":"04b616c9-6937-4ad6-ac25-c7e749052a9e","acronym":"","url":"https://clinicaltrials.gov/study/NCT00175838","created_at":"2022-04-24T08:54:14.281Z","updated_at":"2024-07-02T16:37:26.468Z","phase":"","brief_title":"Primary Thrombocythaemia 1 Trial","source_id_and_acronym":"NCT00175838","lead_sponsor":"University of Cambridge","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e hydroxyurea • aspirin"],"overall_status":"Completed","enrollment":" Enrollment 1398","initiation":"Initiation: 07/01/1997","start_date":" 07/01/1997","primary_txt":" Primary completion: 11/01/2016","primary_completion_date":" 11/01/2016","study_txt":" Completion: 11/01/2016","study_completion_date":" 11/01/2016","last_update_posted":"2017-01-18"},{"id":"4debac25-5f39-463e-8915-abc74602ad24","acronym":"","url":"https://clinicaltrials.gov/study/NCT01259817","created_at":"2021-01-18T05:04:55.274Z","updated_at":"2024-07-02T16:37:26.611Z","phase":"Phase 2","brief_title":"Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)","source_id_and_acronym":"NCT01259817","lead_sponsor":"Ronald Hoffman","biomarkers":" JAK2 • CALR","pipe":" | ","alterations":" JAK2 V617F","tags":["JAK2 • CALR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 V617F"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pegasys (pegylated interferon α -2a) • hydroxyurea • aspirin"],"overall_status":"Completed","enrollment":" Enrollment 135","initiation":"Initiation: 09/01/2011","start_date":" 09/01/2011","primary_txt":" Primary completion: 12/01/2016","primary_completion_date":" 12/01/2016","study_txt":" Completion: 12/01/2016","study_completion_date":" 12/01/2016","last_update_posted":"2017-01-11"}]